Agios Pharmaceuticals Inc (NASDAQ: AGIO)’s stock price has decreased by -5.46 compared to its previous closing price of 58.60. However, the company has seen a 0.58% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-05 that – Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on mitapivat and tebapivat (AG-946), the company’s PK activators, will be featured in oral and poster presentations during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 7-10, 2024.
Is It Worth Investing in Agios Pharmaceuticals Inc (NASDAQ: AGIO) Right Now?
Agios Pharmaceuticals Inc (NASDAQ: AGIO) has a higher price-to-earnings ratio of 4.87x compared to its average ratio, The 36-month beta value for AGIO is at 0.78. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AGIO is 55.28M, and currently, shorts hold a 7.85% of that float. The average trading volume for AGIO on November 15, 2024 was 539.33K shares.
AGIO’s Market Performance
The stock of Agios Pharmaceuticals Inc (AGIO) has seen a 0.58% increase in the past week, with a 26.77% rise in the past month, and a 23.03% gain in the past quarter. The volatility ratio for the week is 5.78%, and the volatility levels for the past 30 days are at 4.50% for AGIO. The simple moving average for the past 20 days is 11.89% for AGIO’s stock, with a 40.80% simple moving average for the past 200 days.
Analysts’ Opinion of AGIO
Raymond James, on the other hand, stated in their research note that they expect to see AGIO reach a price target of $51. The rating they have provided for AGIO stocks is “Outperform” according to the report published on October 10th, 2024.
Leerink Partners gave a rating of “Market Perform” to AGIO, setting the target price at $56 in the report published on September 27th of the current year.
AGIO Trading at 19.82% from the 50-Day Moving Average
After a stumble in the market that brought AGIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.47% of loss for the given period.
Volatility was left at 4.50%, however, over the last 30 days, the volatility rate increased by 5.78%, as shares surge +25.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.79% upper at present.
During the last 5 trading sessions, AGIO rose by +0.58%, which changed the moving average for the period of 200-days by +144.92% in comparison to the 20-day moving average, which settled at $49.51. In addition, Agios Pharmaceuticals Inc saw 148.77% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AGIO starting from Washburn Theodore James Jr., who sale 772 shares at the price of $56.09 back on Nov 08 ’24. After this action, Washburn Theodore James Jr. now owns 813 shares of Agios Pharmaceuticals Inc, valued at $43,301 using the latest closing price.
Ballal Rahul D., the Director of Agios Pharmaceuticals Inc, sale 10,000 shares at $58.19 during a trade that took place back on Nov 08 ’24, which means that Ballal Rahul D. is holding 7,992 shares at $581,911 based on the most recent closing price.
Stock Fundamentals for AGIO
Current profitability levels for the company are sitting at:
- -12.38 for the present operating margin
- 0.76 for the gross margin
The net margin for Agios Pharmaceuticals Inc stands at 20.51. The total capital return value is set at -0.24. Equity return is now at value 53.65, with 48.18 for asset returns.
Based on Agios Pharmaceuticals Inc (AGIO), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -5.41.
Currently, EBITDA for the company is -384.86 million with net debt to EBITDA at -0.27. When we switch over and look at the enterprise to sales, we see a ratio of 90.25. The receivables turnover for the company is 10.54for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.99.
Conclusion
In conclusion, Agios Pharmaceuticals Inc (AGIO) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
